ORYZON Announces End of Patient Recruitment for its Phase IIa trials in aggression with vafidemstat: REIMAGINE and REIMAGINE-AD
MADRID, SPAIN and CAMBRIDGE MA.
• REIMAGINE has recruited 30 patients in three psychiatric disorders: Borderline personality disorder (BPD), Attention deficit and hyperactivity disorder (ADHD) and Autism Spectrum Disorder (ASD)
• REIMAGINE-AD has recruited 12 patients in Alzheimer’s disease
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company has recruited all the planned patients in the ongoing Phase IIa REIMAGINE trials, with a total of 42 patients recruited.